IN APRIL 2015, 24-year-old Irish student Karen Buckley was doing what thousands of students across the country do at the ...

Leaving his violently beaten and traumatized girlfriend in bed, a wealthy Parkland financial adviser stood up, put on a dress shirt and joined a Zoom hearing in his divorce case. Scott Matalon ...

Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of personalized treatment decisions.

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and multiple myeloma, respectively.

Current approved CAR T-cell therapy treatments rely on an ex vivo route, in which a patient’s T cells are removed, genetically engineered to target antigens, and put back into the patient.

A groundbreaking new review comprehensively synthesizes the latest developments in next-generation chimeric antigen receptor T cell (CAR-T) therapies, highlighting key preclinical and clinical ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma. In 2021, the FDA approved idecabtagene vicleucel ...

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.